Bringing deals to life.

5-6th February 2018, etc. venues, 200 Aldersgate, St. Pauls, London EC1A 4HD


2018 Event Partners


The 4th annual Biotech and Money / Medtech and Money World Congress is a high-calibre, senior Executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science companies need to enable more effective  investment, business planning and partnering within their businesses.

With our relentless focus on quality peer-2-peer discussion, high-level networking and partnering, unique formats and a vetted, high-calibre audience, we bring together the people that matter to the future of healthcare and life science funding, finance, investment and deal making.

The 2017 conference officially attracted the largest gathering of active Life Science investors in Europe, making it the go to event for Executives looking to engage in investment and partnering discussions. It's the must attend 2018 event for corporates, investors and pharma.






  • - The 2018 attending companies 
  • - What's new for February 2018
  • - What makes the 2018 event unique
  • - The 2018 agenda and speakers
  • - Who attended in 2017
  • - Plus much more...



Tony Hickson
Managing Director, Imperial Innovations

Tim Luker
Director, Eli Lilly & Co

Daniel O'Mahony
Partner, Seroba Life Sciences

Christoph Ruedig
Partner, Albion Capital

Claudio Rumazza
Partner, Innogest

Alain Huriez
Managing Partner, Advent France Biotechnology

Edoardo Negroni
Managing Partner, AurorA-TT

Gerry Maguire
General Partner, Atlantic Bridge

Giovanni Mariggi
Principal, Medicxi

Edward Van Wezel
Managing Partner, BioGeneration Ventures

James Shaw
Co-Founder, JAG Shaw Baker

Jean-Philippe Combal
CEO, Vivet Therapeutics

Janke Dittmer
Partner, GildeHealthcare

Jennifer Laird
Senior Director, Eli Lilly & Co.

John Zai
CEO, Cocoon Networks

Joachim Rautter
Managing Director, Peppermint

Kate Bingham
Managing Partner, SV Health Investors

Johnston Erwin
Vice President, Eli Lilly & Co.

Jonathan Goldstein
Director, Boston Scientific Ventures

Martin Frost
CEO, Cambridge Medical Robotics

Pascale Auge
CEO, Inserm Transfert

Onno Van De Stolpe
CEO, Galapagos

Piyush Unalkat
Head of Technology Transfer, EIF

Thom Rasche
Partner, Earlybird Venture Capital

Tommi Lehtonen
CEO, Blueprint Genetics

Sander Slootweg
Managing Director, Forbion Capital Partners

Paul Saunders
Head of Innovation Investments, Ireland's Strategic Investment Fund

Paul Ashley
Head of Technology Transfer, Oxford University Innovation

Chandra Leo
Investment Advisor, HBM Partners

Iain Thomas
Head of Life Sciences, Cambridge Enterprise

Rob De Ree
Chairman, Mellon Medical

Steve Atkinson
CEO, Atlantic Therapeutics

Tara Raveendran
Head of Life Sciences Research, Shore Capital

Gita Dittmar
Head of Corporate Development, Ethris

Angus Grant
SVP Business Development, Celgene

Michael Stein
CEO, Oxstem

Pekka Simula
CEO, Herantis Pharma

Christopher Clearly
VP Corporate Development, Medtronic

Tauhid Ali
VP & Head of TAK-celerator, Takeda

Raul Insa
CEO, Som Biotech

Martin Ostermaier
CEO, Interax

Thomas Lienard
CEO, Bone Therapeutics

Randolph Hubbell
CEO, Carmell Therapeutics

Fred Jacobs
CEO, TYG - Oncology

Carlos De Sousa
CEO, Immunicium

Phil L'huillier
Head European Innovation Hub, MSD

Pavithra Sundaresan
Senior Director New Ventures and Transaction Lead, J & J Innovation

Christian Schetter
CEO, Rigontec

Rodger Novak
CEO, Crispr Therapeutics

Miguel Costa
CEO, Aglaris Cell

Theresa Deisher
CEO, AVM Biotechnology

Tushar Singvhi
VP Corporate Development and Investments, Crescent Enterprises

Vanessa Malier
Managing Partner, Kurma Partners

Clive Cookson
Science Editor, Financial Times

Niall Martin
CEO, Artios Pharma

Erica Whittaker
Head of UCB ventures, UCB Pharma

Elaine Warburton
CEO, QuantuMDx

Tim Haines
Managing Partner, Abingworth

Asaf Homossany
Managing Director EMEA, NASDAQ

Adam Kostyal
SVP and Head of European Listings, NASDAQ

Niels Riedemann
CEO, Inflarx

Xavier Bertrand
Global GM Symetis & VP International SH Valves, Boston Scientific

Beverley Carr
Business Development, Immunoinflammation Therapy Area, GSK

Sourabh Pagaria
Senior Vice President and General Manager, Siemens Healthineers

Andrew Shailer- Smith
CEO, Astraveus

David Hipkiss
CEO, Enesi Pharma

Simon Hubbert
CEO, LIG Technologies

Tim Wilson
CEO, IGEM Therapeutics

Paul Ko Ferringno
CEO, Metalinear

Shaun Grady
VP Global Business Development, Astrazeneca

Timm Jessen
CEO, Topas Therapeutics

Jean Christophe Renondin
Senior Investment Manager Healthcare, Oman Investment Fund

Rainer Lichtenberger
CEO, Atriva Therapeutics

Assaf Barnea
CEO, Sanara Ventures

Celine- Lea Halioua- Haubold
CEO, Oisin Biotechnologies

Florence Sejourne
CEO, Da Volterra

Patrick Van Beneden
Partner, GIMV

James Greene
CEO, Medlumics

Pawel Przewielikowski
CEO, Selvita

Isabel Van De Keere
CEO, Immersive Rehab

Henri Francois Boedt
Senior Loan Officer, European Investment Bank

David Berry
General Partner, Flagship Pioneering

Elisa Petris
Partner, Syncona Partners

Joe Anderson
CEO, Arix Biosciences

Philippe Lopes- Fernandes
Head of Global Business Development & Alliance Management, EMD Serono

Naveed Siddiqi
Partner, Edmond De Rothschild Investment Partners

Sarah Howell
CEO, Arecor

Neil Clark
CEO, Destiny Pharma

Richard Davies
CEO, Bone Support

Marc Lemonnier
CEO, Antabio

Pierre Chauvineau
VP, Boston Scientific

Adam Hill
CMO, McLaren Applied Technologies

Isobel Finnie
Partner, Haseltine Lake

Christoph Kausch
Founding Partner & CEO, MTIP Medtech Innovation Partners

Alexia Perouse
CEO, Ibionext Growth Fund

Martin Pfister
Senior Investment Manager, High-Tech Grunderfonds

Jasper Bos
VP & Head of Healthcare, Merck Ventures

Darrin Disley
CEO, Horizon Discovery Group

Edwin Moses
CEO, Ablynx

Timothy Herpin
VP & Head of Transactions and BD, Astrazeneca

Hans Loibner
CEO, Apeiron Biologics

Billy Boyle
CEO, Owlstone Medical

Hubert Birner
Managing Partner, TVM Capital Life Science

Iain Dukes
Venture Partner, OrbiMed

Viktor Drvota
CEO, Karolinska Development

Deborah Harland
Partner, SR- One

Dirk Kersten
Managing Director, Inkef Capital

Nissim Darvish
Senior Managing Director, OrbiMed

Søren Møller
Managing Partner, Novo Seeds

Frank Hensel
Senior Investment Manager, High-Tech Grunderfonds


Address: etc.venues, 200 Aldersgate,

St. Pauls, London, EC1A 4HD

Email: [email protected]

Phone: +44 (0) 20 7105 6090


Address : Suite 125, The Business Design Centre, 52 Upper St, London N1 0QH, UK

Email: [email protected]

Phone: +44 (0) 203 637 5908